文献速递神经肿瘤

胶质瘤T细胞免疫特征及其免疫治疗意义系统综述

T cell immunity in glioma and potential implications for immunotherapy: A systematic review.
PubMed 文献 · Neuro Oncol · 2026-01-01

该系统综述检索至2025年5月6日,从4303篇文章中纳入85项研究,评估IDH突变型与IDH野生型胶质瘤微环境中T细胞的丰度、空间分布与表型特征。结果显示胶质瘤T细胞密度总体偏低且异质,随WHO级别升高和复发而增加;浸润T细胞多为晚期分化表型并表达耗竭标志物,抗肿瘤细胞毒性下降,预后意义尚存争议。

要点

  • 胶质瘤T细胞密度普遍偏低,IDH突变型更低,随WHO级别升高和复发增加。
  • 浸润T细胞呈晚期分化表型,表达PD-1、CTLA-4、TIM-3、LAG-3、CD39和TIGIT等耗竭标志物。
  • T细胞多聚集于血管周围,耗竭表型富集于髓系丰富、缺氧的肿瘤核心区。

核心结论

  • 胶质瘤中T细胞稀少、多为完全分化且功能惰性,理解并重振缺陷的T细胞反应对成功免疫治疗至关重要。

研究设计与样本

  • 系统综述,检索Medline、Embase、Web of Science核心合集、Google Scholar和Cochrane对照试验中心注册库,截至2025年5月6日;筛选4303篇文章后纳入85项研究人类胶质瘤T细胞免疫的研究。

主要发现

  • T细胞存在于胶质瘤微环境但密度异质且总体偏低,尤其在IDH突变型胶质瘤中。
  • T细胞丰度随WHO级别升高和复发而增加,并聚集在血管周围,尤其见于IDH突变型胶质瘤。
  • 胶质瘤浸润T细胞大多呈晚期分化表型(CD45RA-CCR7-C62L-),表达PD-1、CTLA-4、TIM-3、LAG-3、CD39和TIGIT等持续抗原激活与耗竭标志物。
  • 该表型伴随抗肿瘤细胞毒性下降,并在空间上富集于髓系丰富、缺氧的肿瘤核心。
  • 预后意义仍存争议。

临床怎么用

  • 未来研究应结合功能与空间免疫图谱分析,以优化和个体化胶质瘤患者的免疫治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: T cell-based immunotherapies have had limited success in glioma thus far. Here, we evaluate the literature on abundance, spatial distribution and phenotypical characteristics of T cells in the tumor micro-environment (TME) of IDH-mutant and IDH-wildtype glioma, with the aim to understand how these measures relate to immunotherapy resistance and to aid the development of immunotherapies for glioma. METHODS: Medline, Embase, Web of Science Core Collection, Google Scholar and the Cochrane Central Register of Controlled Trials were systematically searched up to May 6, 2025. Out of 4303 articles screened, 85 studies examining T cell immunity in human glioma were selected. We collected information about tumor subtype, grade, methods, T cell abundance, spatial distribution, phenotypes and prognostic significance. RESULTS: T cells are present in the glioma TME, but densities are heterogeneous and generally low, especially in IDH-mutant glioma. T cell abundance increases with higher WHO grade and upon recurrence. T cells cluster around blood vessels, especially in IDH-mutant glioma. Glioma-infiltrating T cells largely display a late-differentiated phenotype (CD45RA-CCR7-C62L-), expressing markers that signify sustained antigen activation and exhaustion (PD-1, CTLA-4, TIM-3, LAG-3, CD39, and TIGIT). This phenotype coincides with decreased anti-tumor cytotoxicity and is spatially enriched in the myeloid-rich, hypoxic tumor core. Prognostic significance remains controversial. CONCLUSIONS: T cells in glioma are scarce, generally fully differentiated and functionally inert. Understanding and reinvigorating the deficient T cell response will be essential for successful immunotherapies. Future research should incorporate functional and spatial immune profiling to optimize and personalize immunotherapeutic strategies for glioma patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Luning R, French PJ, Vanbilloen WJF, et al. T cell immunity in glioma and potential implications for immunotherapy: A systematic review. Neuro Oncol. 2026. PMID: 41105161. doi:10.1093/neuonc/noaf236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。